Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia

Phase 4 Unknown 462 enrolled Qingfeng Pharmaceutical Group

RandomizedParallel-groupDouble-blindSupportive care

Summary

Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia: A Multicenter, Randomized,Double-blinded, Placebo Controlled Clinical Trial. The hypothesis is that combination therapy with Andrographolid Sulfonatein injection and antibacterial is significantly better than antibacterial alone in achieving clinical stability among hospitalized CAP patients.

Timeline

Start: 2016-07
Primary completion: 2019-01
Completion: 2019-06-30

Publications

Shang LH, Fan GH, Chen LP, Liu JH, Wang XG, Liu B, Tian GZ, Chen XS, Yu JX, Yang GR, Su X, Liu XD, Li YP, Xu SF, Lin YH, Cao J, Zhang W, Feng WS, Cai ZG, Wang QH, Wang JX, Wang YG, Chen J, Zhang YX, Cui XJ. Andrographolide Sulfonate Injection for Adjunctive Treatment of Non-severe Community-Acquired Pneumonia in Adults: A Multicenter, Double-Blind, Randomized Controlled Trial. Chin J Integr Med. 2026 Jan 5. doi: 10.1007/s11655-025-3932-8. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	andrographolide sulfonate	Unknown	500 mg	Intravenous
Background	Amoxicillin-clavulantic acid	Unknown	—	—
Background	Azithromycin	Small molecule	—	—
Background	Doxycycline	Small molecule	—	—
Background	Minocycline	Small molecule	—	—

Indications

No indication recorded.